Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Nat Med ; 23(3): 347-354, 2017 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-28112735

RESUMO

The prefrontal cortex (PFC) underlies higher cognitive processes that are modulated by nicotinic acetylcholine receptor (nAChR) activation by cholinergic inputs. PFC spontaneous default activity is altered in neuropsychiatric disorders, including schizophrenia-a disorder that can be accompanied by heavy smoking. Recently, genome-wide association studies (GWAS) identified single-nucleotide polymorphisms (SNPs) in the human CHRNA5 gene, encoding the α5 nAChR subunit, that increase the risks for both smoking and schizophrenia. Mice with altered nAChR gene function exhibit PFC-dependent behavioral deficits, but it is unknown how the corresponding human polymorphisms alter the cellular and circuit mechanisms underlying behavior. Here we show that mice expressing a human α5 SNP exhibit neurocognitive behavioral deficits in social interaction and sensorimotor gating tasks. Two-photon calcium imaging in awake mouse models showed that nicotine can differentially influence PFC pyramidal cell activity by nAChR modulation of layer II/III hierarchical inhibitory circuits. In α5-SNP-expressing and α5-knockout mice, lower activity of vasoactive intestinal polypeptide (VIP) interneurons resulted in an increased somatostatin (SOM) interneuron inhibitory drive over layer II/III pyramidal neurons. The decreased activity observed in α5-SNP-expressing mice resembles the hypofrontality observed in patients with psychiatric disorders, including schizophrenia and addiction. Chronic nicotine administration reversed this hypofrontality, suggesting that administration of nicotine may represent a therapeutic strategy for the treatment of schizophrenia, and a physiological basis for the tendency of patients with schizophrenia to self-medicate by smoking.


Assuntos
Comportamento Animal/efeitos dos fármacos , Inibição Neural/efeitos dos fármacos , Nicotina/farmacologia , Agonistas Nicotínicos/farmacologia , Córtex Pré-Frontal/efeitos dos fármacos , Células Piramidais/efeitos dos fármacos , Comportamento Social , Animais , Sistemas CRISPR-Cas , Modelos Animais de Doenças , Imunofluorescência , Masculino , Camundongos , Camundongos Knockout , Camundongos Transgênicos , Polimorfismo de Nucleotídeo Único , Córtex Pré-Frontal/fisiopatologia , Inibição Pré-Pulso/efeitos dos fármacos , Receptores Adrenérgicos beta 2/genética , Receptores Nicotínicos/genética , Reflexo de Sobressalto/efeitos dos fármacos , Esquizofrenia/genética , Tabagismo/genética , Receptor Nicotínico de Acetilcolina alfa7/genética
2.
Anal Bioanal Chem ; 405(15): 5119-31, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23354577

RESUMO

Infections with Chlamydia pneumoniae cause several respiratory diseases, such as community-acquired pneumonia, bronchitis or sinusitis. Here, we present an integrated non-targeted metabolomics analysis applying ultra-high-resolution mass spectrometry and ultra-performance liquid chromatography mass spectrometry to determine metabolite alterations in C. pneumoniae-infected HEp-2 cells. Most important permutations are elaborated using uni- and multivariate statistical analysis, logD retention time regression and mass defect-based network analysis. Classes of metabolites showing high variations upon infection are lipids, carbohydrates and amino acids. Moreover, we observed several non-annotated compounds as predominantly abundant after infection, which are promising biomarker candidates for drug-target and diagnostic research.


Assuntos
Chlamydophila pneumoniae/fisiologia , Cromatografia Líquida/métodos , Espectrometria de Massas/métodos , Metabolômica/métodos , Biomarcadores , Técnicas de Química Analítica , Células Hep G2 , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA